Back

Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Lipids - Drug therapy 1 Drug therapy ESC Professional Premium Access ESC Congress 2022

About the speakers

Photo
Mr Thomas Michaeli

Mannheim (Germany)

Photo
Doctor Doctor Daniel Tobias Michaeli

University Medical Centre of Mannheim, Mannheim (Germany)

5 More presentations in this session

Presentation thumbnail
Correlation of lipoprotein (a) with parameters of lipid profile and other cardiovascular risk factors in patients with familial combined hyperlipidemia
Doctor I. Andrikou (Athens, GR)
Abstract Slides
Presentation thumbnail
Recurrent atherosclerotic cardiovascular disease events preventable with guideline recommended lipid-lowering treatment following myocardial infarction
Doctor R. Rosenson (New York City, US)
Abstract Slides
Presentation thumbnail
Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients
Doctor A. Bilitou (Munich, DE)
Abstract Slides
Presentation thumbnail
PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study
Doctor C. Basile (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Worldwide comparative efficacy of nutraceuticals on lipid profile. an updated systematic review and network meta-analysis
Doctor T. Osadnik (Zabrze, PL)
Abstract Slides

Access the full session

Session thumbnail
Lipids - Drug therapy 1

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
Fix the plaque, fight the lipids: why low-density lipoproteins still matter after percutaneous coronary intervention
thumbnail
Congress Presentation
What’s new in LDL lowering?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources